Dahlia Garza
Research Subjects
Research Interests
Dahlia Garza has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Martha Mayo
7 shared publications- Bertram Pitt
Department of Cardiology, University of Michigan, Ann Arbor (B.P.).
3 shared publications Daniel Wilson
3 shared publicationsGeorge Bakris
University of Chicago Medicine, Comprehensive Hypertension Center, Chicago, IL
3 shared publicationsLance Berman
Relypsa, Inc., Medical Affairs, Redwood City, CA
3 shared publicationsMatthew Weir
3 shared publications
Latest Publications
- 1 November 2018
- Published by Elsevier in Heart & Lung
- Vol. 47 (6) , 654
Long-term effect of patiromer for hyperkalemia treatment in patients with chronic kidney disease, heart failure, and ejection fraction >40% on RAAS inhibitors
- 1 November 2018
- Published by Elsevier in Heart & Lung
- Vol. 47 (6) , 654
Long-term effect of patiromer for hyperkalemia treatment in patients with chronic kidney disease, heart failure, and ejection fraction >40% on RAAS inhibitors
- 1 August 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (8) , S21
Effect of Patiromer on Serum K+ in Hyperkalemic Patients with Heart Failure (HF): Pooled Results From the AMETHYST-DN, OPAL-HK and TOURMALINE Trials
- 1 August 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (8) , S21
Effect of Patiromer on Serum K+ in Hyperkalemic Patients with Heart Failure (HF): Pooled Results From the AMETHYST-DN, OPAL-HK and TOURMALINE Trials
- 1 May 2017
- Published by Elsevier in Heart & Lung
- Vol. 46 (3) , 215
2 Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors
- 1 May 2017
- Published by Elsevier in Heart & Lung
- Vol. 46 (3) , 215
2 Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors
- 1 April 2017
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 10 (4)
Reassessing Phase II Heart Failure Clinical Trials
The increasing burden and the continued suboptimal outcomes for patients with heart failure underlines the importance of continued research to develop novel therapeutics for this disorder. This can only be accomplished with successful translation of basic science discoveries into direct human application through effective clinical trial design and execution that results in a substantially improved clinical course and outcomes. In this respect, phase II clinical trials play a pivotal role in determining which of the multitude of potential basic science discoveries should move to the large and expansive registration trials in humans. A critical examination of the phase II trials in heart failure reveals multiple shortcomings in their concept, design, execution, and interpretation. To further a dialogue on the challenges and potential for improvement and the role of phase II trials in patients with heart failure, the Food and Drug Administration facilitated a meeting on October 17, 2016, represented by clinicians, researchers, industry members, and regulators. This document summarizes the discussion from this meeting and provides key recommendations for future directions.
- 1 April 2017
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 10 (4)
Reassessing Phase II Heart Failure Clinical Trials
The increasing burden and the continued suboptimal outcomes for patients with heart failure underlines the importance of continued research to develop novel therapeutics for this disorder. This can only be accomplished with successful translation of basic science discoveries into direct human application through effective clinical trial design and execution that results in a substantially improved clinical course and outcomes. In this respect, phase II clinical trials play a pivotal role in determining which of the multitude of potential basic science discoveries should move to the large and expansive registration trials in humans. A critical examination of the phase II trials in heart failure reveals multiple shortcomings in their concept, design, execution, and interpretation. To further a dialogue on the challenges and potential for improvement and the role of phase II trials in patients with heart failure, the Food and Drug Administration facilitated a meeting on October 17, 2016, represented by clinicians, researchers, industry members, and regulators. This document summarizes the discussion from this meeting and provides key recommendations for future directions.
- Open Access
- 14 May 2016
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 31 (suppl_1) , i4
SO010PATIROMER PROTECTED AGAINST RECURRENT HYPERKALEMIA FOR UP TO 52 WEEKS IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) RECEIVING COMBINED RAAS INHIBITOR THERAPY
Introduction and Aims: Renin-angiotensin-aldosterone system inhibitors (RAASi), such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), are preferred first-line drugs in high-risk patients (pts) with diabetes. Dual therapy (D) with an ACE inhibitor and an ARB, or combined therapy in which an ACE and/or ARB is used with a mineralocorticoid antagonist (C), may have greater cardiorenal benefit versus monotherapy in select patients with DKD, and in patients with heart failure. However, the use of D or C RAASi therapy is frequently limited by hyperkalemia (HK).
- 14 May 2016
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 31 (suppl_1) , i4
Open AccessSO010PATIROMER PROTECTED AGAINST RECURRENT HYPERKALEMIA FOR UP TO 52 WEEKS IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) RECEIVING COMBINED RAAS INHIBITOR THERAPY
Introduction and Aims: Renin-angiotensin-aldosterone system inhibitors (RAASi), such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), are preferred first-line drugs in high-risk patients (pts) with diabetes. Dual therapy (D) with an ACE inhibitor and an ARB, or combined therapy in which an ACE and/or ARB is used with a mineralocorticoid antagonist (C), may have greater cardiorenal benefit versus monotherapy in select patients with DKD, and in patients with heart failure. However, the use of D or C RAASi therapy is frequently limited by hyperkalemia (HK).
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S107-S108
Patiromer Reduces Serum K+ in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S107-S108
Patiromer Reduces Serum K+ in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN
- Open Access
- 31 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii51-iii52
SuO019PATIROMER LOWERED SERUM POTASSIUM FOR UP TO 1 YEAR IN HYPERKALEMIC PATIENTS WITH DIABETES AND ADVANCED KIDNEY DISEASE ON RAAS INHIBITORS
Introduction and Aims: Diabetes is a well-recognized risk factor for chronic kidney disease (CKD) and the co-occurrence of CKD in diabetes confers an even higher risk of poor cardiovascular outcomes. Guidelines recommend renin-angiotensin-aldosterone (RAAS) inhibitors to slow the progression of diabetic kidney disease (DKD), however patients with DKD are at high risk for hyperkalemia, which may limit or prevent RAAS inhibitor use. Currently available potassium (K+)-binding agents for hyperkalemia treatment are generally poorly tolerated, which may limit long-term use. AMETHYST-DN evaluated the novel agent patiromer, the active moiety of which is a nonabsorbed potassium (K+)-binder, in a 1-yr trial of patients with diabetes and CKD on RAAS inhibitors. In this post hoc subanalysis, we report the results of long-term patiromer therapy in patients with advanced CKD (stages 4-5).
- 31 May 2015
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 30 (suppl_3) , iii51-iii52
Open AccessSuO019PATIROMER LOWERED SERUM POTASSIUM FOR UP TO 1 YEAR IN HYPERKALEMIC PATIENTS WITH DIABETES AND ADVANCED KIDNEY DISEASE ON RAAS INHIBITORS
Introduction and Aims: Diabetes is a well-recognized risk factor for chronic kidney disease (CKD) and the co-occurrence of CKD in diabetes confers an even higher risk of poor cardiovascular outcomes. Guidelines recommend renin-angiotensin-aldosterone (RAAS) inhibitors to slow the progression of diabetic kidney disease (DKD), however patients with DKD are at high risk for hyperkalemia, which may limit or prevent RAAS inhibitor use. Currently available potassium (K+)-binding agents for hyperkalemia treatment are generally poorly tolerated, which may limit long-term use. AMETHYST-DN evaluated the novel agent patiromer, the active moiety of which is a nonabsorbed potassium (K+)-binder, in a 1-yr trial of patients with diabetes and CKD on RAAS inhibitors. In this post hoc subanalysis, we report the results of long-term patiromer therapy in patients with advanced CKD (stages 4-5).
- Open Access
- 1 January 2010
- Published by S. Karger AG in Cardiology
- Vol. 117 (4) , 301-306
Prognosis of a Normal Positron Emission Tomography 82Rb Myocardial Perfusion Imaging Study in Women with No History of Coronary Disease
Objectives: Myocardial perfusion imaging (MPI) with positron emission tomography (PET) has advantages over single-photon emission computerized tomography, particularly for women. This investigation was undertaken to define the prognosis of a normal stress PET MPI study in women. Methods:The cohort comprised 457 women evaluated for suspected coronary artery disease (CAD) who had normal pharmacologic stress 82Rb PET MPI. No patient had clinically evident CAD. Kaplan-Meier estimates were used to determine death and initial nonfatal cardiac event rates over 7 years. Log rank tests were used to assess the relationship between baseline cardiac risk and events during follow-up, and to contrast survival in the cohort with age- and gender-matched US census comparators. Results: During follow-up, there were 11 deaths (all nonischemic), 3 nonfatal myocardial infarctions, 3 percutaneous coronary interventions and 1 coronary artery bypass operation. Average risks of death and initial nonfatal cardiac events were 0.72 and 0.47% per year, respectively. Cardiac events were associated with a history of diabetes (p < 0.0003) and a family history of CAD (p < 0.05). Conclusion: A normal cardiac PET study is associated with a very low rate of future cardiac events. Women with diabetes and a strong family history of CAD are more likely to sustain events and require close surveillance for the development of coronary disease.
- 1 January 2010
- Published by S. Karger AG in Cardiology
- Vol. 117 (4) , 301-306
Open AccessPrognosis of a Normal Positron Emission Tomography 82Rb Myocardial Perfusion Imaging Study in Women with No History of Coronary Disease
Objectives: Myocardial perfusion imaging (MPI) with positron emission tomography (PET) has advantages over single-photon emission computerized tomography, particularly for women. This investigation was undertaken to define the prognosis of a normal stress PET MPI study in women. Methods:The cohort comprised 457 women evaluated for suspected coronary artery disease (CAD) who had normal pharmacologic stress 82Rb PET MPI. No patient had clinically evident CAD. Kaplan-Meier estimates were used to determine death and initial nonfatal cardiac event rates over 7 years. Log rank tests were used to assess the relationship between baseline cardiac risk and events during follow-up, and to contrast survival in the cohort with age- and gender-matched US census comparators. Results: During follow-up, there were 11 deaths (all nonischemic), 3 nonfatal myocardial infarctions, 3 percutaneous coronary interventions and 1 coronary artery bypass operation. Average risks of death and initial nonfatal cardiac events were 0.72 and 0.47% per year, respectively. Cardiac events were associated with a history of diabetes (p < 0.0003) and a family history of CAD (p < 0.05). Conclusion: A normal cardiac PET study is associated with a very low rate of future cardiac events. Women with diabetes and a strong family history of CAD are more likely to sustain events and require close surveillance for the development of coronary disease.
- 1 March 2009
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 60 (3) , 408-409
Hallucinations: The Science of Idiosyncratic Perception
- 1 March 2009
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 60 (3) , 408-409
Hallucinations: The Science of Idiosyncratic Perception
- 1 January 2004
- Published by Taylor & Francis in Journal of Gay & Lesbian Mental Health
- Vol. 8 (3) , 97-105
The community health project
- 1 January 2004
- Published by Taylor & Francis in Journal of Gay & Lesbian Mental Health
- Vol. 8 (3) , 97-105
The community health project